Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 58Cyclophosphamide 40fludarabine phosphate 27fludarabine 21Lenalidomide 19Mycophenolic Acid 17idelalisib 16Antilymphocyte Serum 16Cyclosporine 15Tacrolimus 13Radiotherapy 13Filgrastim 13venetoclax 12umbralisib 12Whole-Body Irradiation 12Busulfan 12Bendamustine Hydrochloride 12ublituximab 11ibrutinib 11Methotrexate 11Peripheral Blood Stem Cell Transplantation 10Alemtuzumab 10obinutuzumab 9Melphalan 9Chlorambucil 8Bortezomib 8thymoglobulin 7ofatumumab 7Etoposide 7Clofarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × Dimethyl Fumarate × Clear all
NCT02784834 2019-09-19

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

University of California, San Diego

Phase 1 Terminated
2 enrolled 5 charts
LymphoidOther hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡